Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Changyanning Tablet for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
NCT05687435Phase 4Completed
- Start
- Jan 2023
- Primary completion
- Apr 2024
- Modality
- TCM (Traditional Chinese Medicine)
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Irritable bowel syndrome with diarrhea (IBS-D) comparing Changyanning group with Placebo group (2 arms). Primary endpoint: Weekly response rate of abdominal pain and diarrhea at 8 weeks. Started Jan 2023; status: completed.
02
Drugs
Changyanning
03
Conditions
Irritable bowel syndrome with diarrhea (IBS-D)
Beyond the preview
Go deeper on NCT05687435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05687435.